CompuGroup Medical SE & Co. KGaA - Laporan Laba Rugi (TTM)

CompuGroup Medical SE & Co. KGaA
US ˙ OTCPK

Laporan Laba Rugi (TTM)

Laporan Laba Rugi CompuGroup Medical SE & Co. KGaA menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 833 869 915 975 1,021 1,063 1,088 1,116 1,127 1,175 1,214 1,249 1,247 1,228 1,220 1,193 1,189 1,186 1,189 1,201
Change (%) 4.34 5.25 6.53 4.78 4.06 2.42 2.58 0.96 4.22 3.31 2.93 -0.17 -1.54 -0.67 -2.21 -0.28 -0.26 0.19 1.06
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 514 533 567 613 650 689 706 727 743 763 780 792 794 813 816 809 809 784 788 799
Change (%) 3.70 6.41 8.00 6.07 6.03 2.47 2.92 2.22 2.71 2.26 1.49 0.29 2.38 0.33 -0.88 0.01 -3.02 0.47 1.37
% of Revenue 61.72 61.35 62.02 62.88 63.65 64.85 64.88 65.10 65.91 64.96 64.29 63.40 63.69 66.22 66.89 67.79 67.99 66.11 66.30 66.50
Gross Operating Profit 319 336 347 362 371 374 382 390 384 412 433 457 453 415 404 384 381 402 401 402
Change (%) 5.37 3.42 4.12 2.60 0.63 2.32 1.94 -1.39 7.15 5.26 5.52 -0.97 -8.41 -2.62 -4.88 -0.91 5.61 -0.36 0.46
% of Revenue 38.28 38.65 37.98 37.12 36.35 35.15 35.12 34.90 34.09 35.04 35.71 36.60 36.31 33.78 33.11 32.21 32.01 33.89 33.70 33.50
SG&A 11 13 13 14 14 18 18 17 16 22 25 25 26 23 20 22 23 22 25 24
Change (%) 22.13 -0.38 5.12 2.07 29.55 -3.31 -4.61 -5.00 37.30 13.62 1.62 4.01 -11.24 -12.69 10.17 3.49 -4.72 11.74 -2.12
% of Revenue 1.29 1.51 1.43 1.41 1.37 1.71 1.61 1.50 1.41 1.86 2.05 2.02 2.10 1.90 1.67 1.88 1.95 1.86 2.08 2.01
R&D
Change (%)
% of Revenue
OpEx 714 749 800 860 916 956 980 1,016 1,038 1,076 1,102 1,108 1,101 1,105 1,095 1,093 1,095 1,088 1,104 1,125
Change (%) 4.97 6.87 7.40 6.56 4.37 2.50 3.72 2.13 3.68 2.40 0.54 -0.61 0.36 -0.91 -0.19 0.18 -0.61 1.42 1.89
% of Revenue 85.66 86.17 87.49 88.21 89.71 89.97 90.04 91.04 92.09 91.61 90.81 88.70 88.31 90.01 89.79 91.64 92.07 91.75 92.87 93.63
Operating Income 119 120 114 115 105 107 108 100 89 99 112 141 146 123 124 100 94 98 85 77
Change (%) 0.58 -4.81 0.42 -8.49 1.42 1.70 -7.74 -10.90 10.57 13.21 26.56 3.24 -15.87 1.48 -19.91 -5.43 3.86 -13.44 -9.70
% of Revenue 14.34 13.83 12.51 11.79 10.29 10.03 9.96 8.96 7.91 8.39 9.19 11.30 11.69 9.99 10.21 8.36 7.93 8.25 7.13 6.37
Interest Expense -8 -5 -3 -3 -5 -5 -7 -8 -9 -25 -17 -27 -24 -24 -28 -30 -31 -31 -31
Change (%) -33.50 -34.55 -4.76 41.13 15.86 18.96 11.21 175.84 -34.30 62.23 -9.29 -0.42 17.67 6.45 3.60 -2.53 0.83
% of Revenue -0.96 -0.61 -0.38 -0.34 -0.46 -0.51 -0.62 -0.73 -0.78 -2.07 -1.32 -2.15 -1.98 -1.99 -2.39 -2.55 -2.65 -2.58 -2.57
Net Income 77 73 71 72 66 69 76 71 72 73 70 89 76 46 50 32 25 35 27 18
Change (%) -5.16 -2.35 1.18 -8.82 4.60 10.49 -6.69 1.32 1.89 -5.22 27.92 -15.04 -39.28 9.01 -35.08 -22.55 37.49 -21.97 -32.41
% of Revenue 9.26 8.42 7.81 7.42 6.46 6.49 7.00 6.37 6.39 6.25 5.73 7.12 6.06 3.74 4.10 2.72 2.12 2.92 2.27 1.52

Source: Capital IQ

Other Listings
DE:COP
GB:0MSD € 16.22
AT:COP2
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista